On April 23, AstraZeneca
- Net sales increased by 12.7%, driven by sales of Nexium, Seroquel, and Crestor.
- The company expects to launch Symbicort, one of its key products, in the U.S. in fiscal 2007.
- On April 23, the company announced that it is to acquire MedImmune
(NASDAQ:MEDI)for $58 per share with a total enterprise value of $15.2 billion. One Fool doesn't think too much of this deal.
(Figures in millions, except per-share data.)Income Statement Highlights
Get back to basics with the income statement.
Margins are the earnings engine.
Balance Sheet Highlights
Cash + ST Invest.
The balance sheet reflects the company's health.
Cash Flow Highlights
Cash From Ops.
Free Cash Flow
Free cash flow is a Fool's best friend.
- A Fresh Outlook at AstraZeneca
- GlaxoSmithKline Gets Ready for the Vaccine Wars
- Genentech Is Still Healthy
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
More from The Motley Fool
3 Dividend Stocks That Pay You More Than IBM Does
The tech titan is a solid dividend stock, but here are others that will get you an even higher yield.
3 High-Yield Dividend Stocks to Buy in 2018
These 3 Big Pharma stocks may be worth adding to your portfolio in 2018.
3 High-Yield International Stocks
These three foreign dividend stocks could be great buys right now. Here's why.